1 |
Hutchinson, C. R. 1995. Anthracyclines. Biotechnology 128, 331-357.
|
2 |
John, A. and Tuszynski, G. 2001. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23.
DOI
ScienceOn
|
3 |
Lal, S., Mahajan, A., Chen, W. N. and Chowbay, B. 2010. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11, 115-128.
DOI
|
4 |
Lambert, E., Dasse, E., Haye, B. and Petitfrere, E. 2004. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49, 187-198.
DOI
ScienceOn
|
5 |
Lin, X., Shang, X., Manorek, G. and Howell, S. B. 2013. Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PLoSOne 8, e67496.
DOI
|
6 |
Liu, Y., Miao, Y., Wang, J., Lin, X., Wang, L., Xu, H. T. and Wang, E. H. 2013. DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1. Int J Mol Med 31, 855-860.
|
7 |
Agarwal, R., D'Souza, T. and Morin, P. J. 2005. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65, 7378-7385.
DOI
ScienceOn
|
8 |
Angelow, S. and Yu, A. S. 2007. Claudins and paracellular transport: an update. Curr Opin Nephrol Hypertens 16, 459-464.
DOI
ScienceOn
|
9 |
Gibbs, D. F., Warner, R. L., Weiss, S. J., Johnson, K. J. and Varani, J. 1999. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol 20, 1136-1144.
DOI
ScienceOn
|
10 |
Weber, T. G., Pöschinger, T., Galbán, S., Rehemtulla, A. and Scheuer, W. 2013. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with Doxorubicin. Neoplasia 15, 863-874.
DOI
|
11 |
Yoon, C. H., Kim, M. J., Park, M. J., Park, I. C., Hwang, S. G., An, S., Choi, Y. H., Yoon, G. and Lee, S. J. 2010. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCd) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 285, 226-233.
DOI
ScienceOn
|
12 |
Zuryn, A., Litwiniec, A., Gackowska, L., Pawlik, A., Grzanka, A. A. and Grzanka, A. 2012. Expression of cyclin A, B1 and D1 after induction of cell cycle arrest in the Jurkat cell line exposed to doxorubicin. Cell Biol Int 36, 1129-1135.
DOI
|
13 |
Rangel, L. B., Agarwal, R., D'Souza, T., Pizer, E. S., Alò, P. L., Lancaster, W. D., Gregoire, L., Schwartz, D. R., Cho, K. R. and Morin, P. J. 2003. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9, 2567-2575.
|
14 |
Minisini, A. M., Andreetta, C., Fasola, G. and Puglisi, F. 2008. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev Anticancer Ther 8, 331-342.
DOI
|
15 |
Mook, O. R., Frederiks, W. M. and Van Noorden, C. J. 2004. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705, 69-89.
|
16 |
Morin, P. J. 2005. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65, 9603-9606.
DOI
ScienceOn
|
17 |
Uzui, H., Harpf, A., Liu, M., Doherty, T. M., Shukla, A. and Chai, N. 2002. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 106, 3024-3030.
DOI
ScienceOn
|
18 |
Vihinen, P., Ala-aho, R. and Kahari, V. M. 2005. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5, 203-220.
DOI
ScienceOn
|
19 |
Turksen, K. and Troy, T. C. 2011. Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 1816, 73-79.
|
20 |
Utech, M., Bruwer, M. and Nusrat, A. 2006. Tight junctions and cell-cell interactions. Methods Mol Biol 341, 185-195.
|
21 |
Wang, Z., Yu, Y., Dai, W., Lu, J., Cui, J., Wu, H., Yuan, L., Zhang, H., Wang, X., Wang, J., Zhang, X. and Zhang, Q. 2012. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 33, 8451-8460.
DOI
|
22 |
Singh, A. B., Sharma, A. and Dhawan, P. 2010. Claudin family of proteins and cancer: an overview. J Oncol 2010, 541957.
|
23 |
Rathos, M. J., Khanwalkar, H., Joshi, K., Manohar, S. M. and Joshi, K. S. 2013. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13, 29.
DOI
|
24 |
Schneeberger, E. E. and Lynch, R. D. 2004. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286, C1213-1228.
DOI
ScienceOn
|
25 |
Shang, X., Lin, X., Alvarez, E., Manorek, G. and Howell, S. B. 2012. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia 14, 974-985.
DOI
|
26 |
Soler, A. P., Miller, R. D., Laughlin, K. V., Carp, N. Z., Klurfeld, D. M. and Mullin, J. M. 1999. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20, 1425-1431.
DOI
ScienceOn
|
27 |
Huang, J., Yang, J., Maity, B., Mayuzumi, D. and Fisher, R. A. 2011. Regulator of G protein signaling 6 mediates doxorubicin- induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res 71, 6310-6319.
DOI
|
28 |
Hutchinson, C. R. and Colombo, A. L. 1999. Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. J Ind Microbiol Biotechnol 23, 647-652.
DOI
ScienceOn
|
29 |
Grant-Tschudy, K. S. and Wira, C. R. 2005. Effect of oestradiol on mouse uterine epithelial cell tumour necrosis factor- alpha release is mediated through uterine stromal cells. Immunology 115, 99-107.
DOI
ScienceOn
|
30 |
Grenader, T., Goldberg, A., Hadas-Halperin, I. and Gabizon, A. 2009. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 20, 15-20.
DOI
|